United States
Germany
Japan
United Kingdom
China
Products
Recombinant Anti-EGFR (Clone Matuzumab)
| Applications | Bl, ELISA, FC, IF, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone S3 12D)
| Applications | ELISA, ICC, IF, IHC, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone 528)
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone 2F8 (Zalutumumab; HuMax-EGFR))
| Applications | ELISA, FC, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone Matuzumab)
| Applications | Bl, ELISA, FC, IF, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone S3 12D)
| Applications | ELISA, ICC, IF, IHC, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone 528)
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human |
Recombinant Anti-EGFR domain III (Clone h-R3 (Nimotuzumab))
| Applications | Bl, FC, IHC |
| Reactivities | Human |
Recombinant Anti-EGFR domain III (Clone h-R3 (Nimotuzumab))
| Applications | Bl, FC, IHC |
| Reactivities | Human |
Recombinant Anti-EGFR domain III (Clone h-R3 (Nimotuzumab))
| Applications | Bl, FC, IHC |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone 2F8 (Zalutumumab; HuMax-EGFR))
| Applications | ELISA, FC, WB |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone C225 (Cetuximab))
| Applications | Bl, FC |
| Reactivities | Human |
Recombinant Anti-EGFR (Clone C225 (Cetuximab))
| Applications | Bl, FC |
| Reactivities | Human |
